Home » Stocks » SNN

Smith & Nephew PLC (SNN)

Stock Price: $37.86 USD -0.19 (-0.49%)
Updated Mar 5, 2021 10:45 AM EST - Market open
Market Cap 16.50B
Revenue (ttm) 4.56B
Net Income (ttm) 448.00M
Shares Out 885.21M
EPS (ttm) 1.02
PE Ratio 36.97
Forward PE 21.51
Dividend $0.38
Dividend Yield 0.99%
Trading Day March 5
Last Price $37.86
Previous Close $38.04
Change ($) -0.19
Change (%) -0.49%
Day's Open 38.25
Day's Range 37.85 - 38.26
Day's Volume 103,852
52-Week Range 25.52 - 46.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 weeks ago

Medical device maker Smith & Nephew plc (NYSE: SNN) slips in the premarket after reporting a slump in revenues and profits. Full-year 2020 revenue fell 11.2% Y/Y to $4.6 billion, and operating...

Proactive Investors - 2 weeks ago

Smith & Nephew PLC (LON:SN) saw its shares slide in early deals as it caught the market on the hop with a disappointing set of results. Shares in the wound care and knee & hip implants special...

Zacks Investment Research - 1 month ago

Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.

PRNewsWire - 1 month ago

LONDON, Jan. 27, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negativ...

InvestorPlace - 1 month ago

The rally in 2020 may mean many stocks are not cheap any more, but long-term investors can still find robust stocks to buy in a bull market The post 7 Stocks to Buy for a Continued Run with th...

Other stocks mentioned: ATVI, BFOR, BLCN, ROKU, TWTR, UNH
Zacks Investment Research - 2 months ago

Let's see if Smith & Nephew plc (SNN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Seeking Alpha - 3 months ago

Smith & Nephew has a solid, growing business which will grow with market growth as well as by acquisition. It has a decent dividend payment history.

InvestorPlace - 4 months ago

These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election. The post 7 Healthcare Stocks That Can Survive Massive Re...

Other stocks mentioned: BMY, CVS, ISRG, MDRX, XPH, TDOC
Seeking Alpha - 4 months ago

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q3 2020 Results - Earnings Call Transcript

Invezz - 5 months ago

In an announcement on Thursday, Smith & Nephew plc (LON: SN) said its underlying revenue is expected to see a 4% decline in the fiscal third quarter. Underlying revenue does not account for no...

Market Watch - 5 months ago

Smith & Nephew SNN, +2.16% SN, -0.91% said it's buying the extremity orthopedics unit of Integra LifeSciences IART, ...

Other stocks mentioned: IART
PRNewsWire - 6 months ago

LONDON, Sept. 2, 2020 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its NOVOSTITCH PRO Meniscal Repair System in Europe...

Zacks Investment Research - 6 months ago

With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.

Seeking Alpha - 7 months ago

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q2 2020 Results - Earnings Call Transcript

The Motley Fool - 7 months ago

The pandemic hit Zimmer, Smith+Nephew, and Stryker hard -- but they'll soon rise again.

Other stocks mentioned: SYK, ZBH
The Motley Fool - 11 months ago

Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Other stocks mentioned: BDX, F, FCAU, GM, JNJ, MDT, NUVA, PHG, RMD, SYK, TSLA, WMGI, ZBH
Seeking Alpha - 1 year ago

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.

Zacks Investment Research - 1 year ago

Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.

The Motley Fool - 1 year ago

Its chief executive's sudden exit sent the stock reeling.

Seeking Alpha - 1 year ago

Smith & Nephew PLC (SNN) Management on Q3 2019 Results - Earnings Call Transcript

Reuters - 1 year ago

Smith+Nephew Plc Chief Executive Namal Nawana is stepping down after just 17 months in the role after becoming dissatisfied with his salary at the medical device maker.

Zacks Investment Research - 1 year ago

This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.

Zacks Investment Research - 1 year ago

Smith & Nephew (SNN) has been gaining from several positive developments of late.

Seeking Alpha - 1 year ago

Smith & Nephew PLC (SNN) CEO Namal Nawana on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.

Zacks Investment Research - 1 year ago

The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.

Seeking Alpha - 1 year ago

Smith & Nephew PLC (SNN) CEO Namal Nawana on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Smith & Nephew has been gaining investor confidence on consistently positive results.

Seeking Alpha - 1 year ago

On March 12, 2019, Osiris Therapeutics disclosed that Smith & Nephew agreed to acquire the company for $660 million.

Other stocks mentioned: OSIR

About SNN

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive ... [Read more...]

Industry
Medical Devices
IPO Date
Nov 16, 1999
CEO
Roland Diggelmann
Employees
18,000
Stock Exchange
NYSE
Ticker Symbol
SNN
Full Company Profile

Financial Performance

In 2020, Smith & Nephew's revenue was $4.56 billion, a decrease of -11.25% compared to the previous year's $5.14 billion. Earnings were $448.00 million, a decrease of -25.33%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Smith & Nephew stock is "Buy." The 12-month stock price forecast is 49.50, which is an increase of 30.76% from the latest price.

Price Target
$49.50
(30.76% upside)
Analyst Consensus: Buy